$RFL News

Rafael Holdings: The Second Half Of Calendar 2026 Could Define This Company Forever

Rafael Holdings Q3 EPS $(0.08) Up From $(0.19) YoY, Sales $179.000K Down From $362.000K YoY

Rafael Holdings Announces Last Patient Completed Final 96-Week Study Visit In Pivotal Phase 3 TransportNPC Study Evaluating Trappsol Cyclo For Treatment Of Niemann-Pick Disease Type C; Topline Results Expected In H2 Of Calendar 2026

Rafael Holdings Insider Ups Holding By 1,810% During Year

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”

Rafael Holdings' Cyclo Therapeutics Enters Into Exclusive Licensing Agreement With MIT For Small Molecules To Improve Myelination In Apoe4 Positive Alzheimer's Disease

Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

Rafael Holdings Q2 EPS $(0.13) Up From $(0.19) YoY, Sales $211.000K Up From $77.000K YoY

Evaluating Alzheimer's Disease Treatments

12 Health Care Stocks Moving In Monday's Intraday Session

Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results

One Rafael Holdings Insider Raised Stake By 1,810% In Previous Year

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

Rafael Holdings Q4 EPS $(0.28) Down From $(0.19) YoY, Sales $350.000K Up From $165.000K YoY

Rafael Holdings Q4 EPS $(0.28) Down From $(0.19) YoY, Sales $350.000K Up From $165.000K YoY

Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

Rafael Holdings Presents Preliminary Phase 3 TransportNPC Data At 15th International Congress of Inborn Errors of Metabolism

Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)

Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data